Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pfizer Presses FDA To Revise Combo Drug Exclusivity Policy For Duavee

Executive Summary

Citizen petition seeks five-year NCE exclusivity for Pfizer’s estrogen/bazedoxifene combo after district court tells FDA its inconsistent position is unreasonable.

Advertisement

Related Content

Ferring Wins In Combo Exclusivity Case; FDA Lacks 'Legitimate Reason' To Reject
All Over But The Lawsuits? NCE Exclusivity For Fixed-Dose Combos Remains Prospective

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register